Developing therapeutic monoclonal antibodies and ADC's is a key focus of the pharmaceutical industry's R&D. The European Antibody Congress 2012 bought together senior level executives and opinion leaders from around the globe to further their knowledge and engage in discussion on a variety of topics relating to mAbs, ADC's and bispecifics. Attendees at this highly successful event were fortunate enough to hear this exciting presentation delivered by Bertrand Coiffier, Professor of Hematology, Hospices Civils de Lyon & UniversitÃ© Lyon 1, âAntibody drug conjugates in haematology'.
This presentation focuses on:
Â· Interest of antibody-drug conjugates
Â· Outlining the uses for treating lymphomas
Â· Exploring the possibilities for using in the treatment leukemias
Are you interested in learning more and engaging in discussion on mAbs, ADC's, bispecifics and antibody biosimilars? Do you want to hear the most recent updates on mAbs/ADC's at the clinical stage? Do you want to network with senior executives and opinion leaders from truly international antibody pioneers? Take a look at the European Antibody Congress 2013.